The Limited Times

Now you can see non-English news...

[Transferring stock] Tailing Pharmaceutical's drug "Shusi" received a consensus evaluation and the stock price rose by 20%

2020-02-21T02:26:45.234Z


Tailing Pharmaceutical (1011) announced that the company's subsidiary Suzhou First Pharmaceutical Co., Ltd., a compound drug for the treatment of bipolar disorder "Shusi" (general name: quetiapine fumarate tablet) recently Nikkei Chinese country


Financial news

Written by: Jingjing He

2020-02-21 10:15

Last updated: 2020-02-21 10:15

Tailing Pharmaceutical (1011) announced that the company's subsidiary Suzhou First Pharmaceutical Co., Ltd., a compound drug for the treatment of bipolar disorder "Shusi" (general name: quetiapine fumarate tablet) recently Nikkei China State Food and Drug Administration approved the consistency evaluation. The company stated that after the "Shu Si" passed the consistency evaluation, it will further consolidate the Group's market position as a domestic psychiatric treatment.

Stimulated by the news, Tailing Pharmaceutical's stock price soared to 0.27 yuan, up to 0.237 yuan, up 19%, and temporarily recorded 11.22 million yuan in transactions.

Transaction stock

Source: hk1

All news articles on 2020-02-21

You may like

News/Politics 2024-02-26T17:32:38.226Z
News/Politics 2024-02-15T09:52:01.059Z
News/Politics 2024-03-27T13:15:35.086Z

Trends 24h

News/Politics 2024-03-27T16:45:54.081Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.